BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748. [PMID: 12480430 DOI: 10.1016/s0140-6736(02)11672-2] [Cited by in Crossref: 344] [Cited by in F6Publishing: 112] [Article Influence: 17.2] [Reference Citation Analysis]
Number Citing Articles
1 Zaaqoq AM, Khasawneh FA, Smalligan RD. Cardiovascular Complications of HIV-Associated Immune Dysfunction. Cardiol Res Pract 2015;2015:302638. [PMID: 25648075 DOI: 10.1155/2015/302638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
2 Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, Hoh R, Martin JN, McCune JM, Waters DD, Deeks SG. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006;20:2275-83. [PMID: 17117013 DOI: 10.1097/QAD.0b013e3280108704] [Cited by in Crossref: 213] [Cited by in F6Publishing: 134] [Article Influence: 13.3] [Reference Citation Analysis]
3 Martínez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, Berenguer J, Domingo P, Moreno X, Perez I, Pich J, Gatell JM; SPIRAL Trial Group. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012;26:2315-26. [PMID: 23018438 DOI: 10.1097/QAD.0b013e328359f29c] [Cited by in Crossref: 91] [Cited by in F6Publishing: 52] [Article Influence: 9.1] [Reference Citation Analysis]
4 Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep 2005;2:132-9. [PMID: 16091260 DOI: 10.1007/s11904-005-0006-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
5 Williams P, Wu J, Cohn S, Koletar S, McCutchan J, Murphy R, Currier J; AIDS Clinical Trials Group 362 Study Team. Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 2009;10:290-301. [PMID: 19220493 DOI: 10.1111/j.1468-1293.2008.00685.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA. Immune activation and collateral damage in AIDS pathogenesis. Front Immunol 2013;4:298. [PMID: 24133492 DOI: 10.3389/fimmu.2013.00298] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
7 Alvi RM, Zanni MV, Neilan AM, Hassan MZO, Tariq N, Zhang L, Afshar M, Banerji D, Mulligan CP, Rokicki A, Awadalla M, Januzzi JL, Neilan TG. Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure. Clin Infect Dis 2020;71:1306-15. [PMID: 31740919 DOI: 10.1093/cid/ciz958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection: . AIDS 2004;18:11-8. [DOI: 10.1097/00002030-200401001-00003] [Cited by in Crossref: 120] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
9 van den Berg-Wolf M, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS 2008;22:483-8. [PMID: 18462073 DOI: 10.1089/apc.2007.0206] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
10 Cavalcanti LRP, Sá MPBO, Perazzo ÁM, Escorel Neto AC, Gomes RAF, Weymann A, Zhigalov K, Ruhparwar A, Lima RC. Mitral Annular Calcification: Association with Atherosclerosis and Clinical Implications. Curr Atheroscler Rep 2020;22:9. [PMID: 32034516 DOI: 10.1007/s11883-020-0825-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ross AC, Armentrout R, O'Riordan MA, Storer N, Rizk N, Harrill D, El Bejjani D, McComsey GA. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008;49:499-506. [PMID: 18989230 DOI: 10.1097/QAI.0b013e318189a794] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
12 . 8.0 Antiretroviral therapy in specific populations: BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13:57-81. [DOI: 10.1111/j.1468-1293.2012.01029_9.x] [Reference Citation Analysis]
13 Domingo P, Labarga P, Palacios R, Guerro MF, Terrón JA, Elías MJ, Santos J, Ruiz MI, Llibre JM; RECOVER Study Group. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004;18:1475-8. [PMID: 15199328 DOI: 10.1097/01.aids.0000131343.53419.04] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
14 Chow DC, Stein JH, Seto TB, Mitchell C, Sriratanaviriyakul N, Grandinetti A, Gerschenson M, Shiramizu B, Souza S, Shikuma C. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS 2010;24:1019-23. [PMID: 20216298 DOI: 10.1097/QAD.0b013e3283383016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lebech AM, Gerstoft J, Hesse B, Petersen CL, Kjaer A. Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am Heart J 2004;147:482-8. [PMID: 14999198 DOI: 10.1016/j.ahj.2003.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
16 de Gaetano Donati K, Cauda R, Iacoviello L. HIV Infection, Antiretroviral Therapy and Cardiovascular Risk. Mediterr J Hematol Infect Dis 2010;2:e2010034. [PMID: 21776340 DOI: 10.4084/MJHID.2010.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
17 Lamers SL, Salemi M, Galligan DC, Morris A, Gray R, Fogel G, Zhao L, McGrath MS. Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol 2010;16:230-41. [PMID: 20367240 DOI: 10.3109/13550281003735709] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
18 Kim RJ, Rutstein RM. Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients. Paediatr Drugs 2010;12:187-99. [PMID: 20481647 DOI: 10.2165/11532520-000000000-00000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
19 Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, Lees RS, Lee H, Grinspoon S. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4916-24. [PMID: 17003092 DOI: 10.1210/jc.2006-1140] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
20 Wilson ME, Allred KF, Kordik EM, Jasper DK, Rosewell AN, Bisotti AJ. Gender-specific effects of HIV protease inhibitors on body mass in mice. AIDS Res Ther 2007;4:8. [PMID: 17472747 DOI: 10.1186/1742-6405-4-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Mogadam E, King K, Shriner K, Chu K, Sondergaard A, Young K, Naghavi M, Kloner RA. The association of nadir CD4-T cell count and endothelial dysfunction in a healthy HIV cohort without major cardiovascular risk factors. SAGE Open Med 2020;8:2050312120924892. [PMID: 32537154 DOI: 10.1177/2050312120924892] [Reference Citation Analysis]
22 Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, Ganz P, Hsue PY. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010;24:1897-905. [PMID: 20543654 DOI: 10.1097/QAD.0b013e32833bee44] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
23 Han SN, Sun XY, Zhang Z, Zhang LR. The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane. Acta Pharmacol Sin 2015;36:454-62. [PMID: 25832426 DOI: 10.1038/aps.2014.165] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
24 Mpondo BC. HIV Infection in the Elderly: Arising Challenges. J Aging Res 2016;2016:2404857. [PMID: 27595022 DOI: 10.1155/2016/2404857] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
25 Murphy RL. Reviving Protease Inhibitors: New Data and More Options. JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;33:S43???S52. [DOI: 10.1097/00126334-200306011-00005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Rezaeian P, Miller PE, Haberlen SA, Razipour A, Bahrami H, Castillo R, Witt MD, Kingsley L, Palella FJ Jr, Nakanishi R, Matsumoto S, Alani A, Jacobson LP, Post WS, Budoff MJ. Extra-coronary calcification (aortic valve calcification, mitral annular calcification, aortic valve ring calcification and thoracic aortic calcification) in HIV seropositive and seronegative men: Multicenter AIDS Cohort Study. J Cardiovasc Comput Tomogr 2016;10:229-36. [PMID: 26949197 DOI: 10.1016/j.jcct.2016.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Neumann T, Lülsdorf KA, Krings P, Reinsch N, Erbel R. [Coronary artery disease in HIV-infected subjects. Results of 101 coronary angiographies]. Herz 2011;36:18-23. [PMID: 21181097 DOI: 10.1007/s00059-010-3410-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Lebech AM, Kristoffersen US, Wiinberg N, Kofoed K, Andersen O, Hesse B, Petersen CL, Gerstoft J, Kjaer A. Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. Eur J Nucl Med Mol Imaging 2008;35:2049-58. [PMID: 18661131 DOI: 10.1007/s00259-008-0846-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
29 Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 2008;56:752-69. [PMID: 18525451 DOI: 10.1097/JIM.0b013e3181788d15] [Cited by in Crossref: 63] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
30 Parienti J, Verdon R. Névirapine et risque cardiovasculaire. Médecine et Maladies Infectieuses 2010;40:499-505. [DOI: 10.1016/j.medmal.2010.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Carr A, Grund B, Neuhaus J, El-Sadr WM, Grandits G, Gibert C, Prineas RJ; SMART Study Investigators. Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS 2008;22:257-67. [PMID: 18097228 DOI: 10.1097/QAD.0b013e3282f20a77] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
32 Torre D, Speranza F, Martegani R. Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection. HIV Med 2005;6:66-78. [PMID: 15807712 DOI: 10.1111/j.1468-1293.2005.00268.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
33 Andrade AC, Ladeia AM, Netto EM, Mascarenhas A, Cotter B, Benson CA, Badaró R. Cross-sectional study of endothelial function in HIV-infected patients in Brazil. AIDS Res Hum Retroviruses 2008;24:27-33. [PMID: 18275345 DOI: 10.1089/aid.2006.0281] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
34 Gopal M, Bhaskaran A, Khalife WI, Barbagelata A. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Curr Cardiol Rev 2009;5:149-54. [PMID: 20436855 DOI: 10.2174/157340309788166705] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
35 Williams PL, Correia K, Karalius B, Van Dyke RB, Wilkinson JD, Shearer WT, Colan SD, Lipshultz SE; Pediatric HIV/AIDS Cohort Study. Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. AIDS 2018;32:2337-46. [PMID: 30102660 DOI: 10.1097/QAD.0000000000001988] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
36 Liu XM, Durante ZE, Peyton KJ, Durante W. Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction. Free Radic Biol Med 2016;94:218-29. [PMID: 26968795 DOI: 10.1016/j.freeradbiomed.2016.03.003] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
37 Konin C, Anzouan-Kacou JB, Essam N'loo A. Arterial thrombosis in patients with human immunodeficiency virus: two-case reports and review of the literature. Case Rep Vasc Med 2011;2011:847241. [PMID: 22937467 DOI: 10.1155/2011/847241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
38 Barbaro G, Barbarini G. Human immunodeficiency virus & cardiovascular risk. Indian J Med Res 2011;134:898-903. [PMID: 22310821 DOI: 10.4103/0971-5916.92634] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
39 Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now? Curr HIV/AIDS Rep 2015;12:375-87. [PMID: 26423407 DOI: 10.1007/s11904-015-0284-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
40 Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, Lewis R, Xu Y, DiNubile MJ. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003;19:449-55. [PMID: 12882653 DOI: 10.1089/088922203766774487] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
41 Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008;22:1615-24. [PMID: 18670221 DOI: 10.1097/QAD.0b013e328300581d] [Cited by in Crossref: 195] [Cited by in F6Publishing: 133] [Article Influence: 13.9] [Reference Citation Analysis]
42 Shahrir S, Crothers K. HIV and Cardiovascular Disease: The Impact of Cigarette Smoking. Curr Cardiovasc Risk Rep 2011;5:492-500. [DOI: 10.1007/s12170-011-0197-x] [Reference Citation Analysis]
43 Kausalya B, Saravanan S, Pallikkuth S, Pahwa R, Saini SR, Iqbal S, Solomon S, Murugavel KG, Poongulali S, Kumarasamy N, Pahwa S. Immune correlates of cardiovascular co-morbidity in HIV infected participants from South India. BMC Immunol 2022;23:24. [PMID: 35581554 DOI: 10.1186/s12865-022-00498-0] [Reference Citation Analysis]
44 Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 2008;22 Suppl 3:S19-26. [PMID: 18845918 DOI: 10.1097/01.aids.0000327512.76126.6e] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
45 Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, Neau D, Cazanave C, Pellegrin JL, Dabis F, Morlat P, Chêne G; GECSA study group. Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort. PLoS One 2014;9:e102671. [PMID: 25076050 DOI: 10.1371/journal.pone.0102671] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
46 Dau B, Holodniy M. The Relationship Between HIV Infection and Cardiovascular Disease. Curr Cardiol Rev 2008;4:203-18. [PMID: 19936197 DOI: 10.2174/157340308785160589] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
47 Seaberg EC, Benning L, Sharrett AR, Lazar JM, Hodis HN, Mack WJ, Siedner MJ, Phair JP, Kingsley LA, Kaplan RC. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke. 2010;41:2163-2170. [PMID: 20798374 DOI: 10.1161/strokeaha.110.583856] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
48 Zhu L, Ma Y, Kiesewetter DO, Wang Y, Lang L, Lee S, Niu G, Chen X. Rational design of matrix metalloproteinase-13 activatable probes for enhanced specificity. ACS Chem Biol 2014;9:510-6. [PMID: 24266806 DOI: 10.1021/cb400698s] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
49 Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, Kimaiyo S. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PLoS One. 2011;6:e22288. [PMID: 21779407 DOI: 10.1371/journal.pone.0022288] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
50 Echeverría P, Domingo P, Llibre JM, Gutierrez M, Mateo G, Puig J, Bonjoch A, Pérez-Alvarez N, Sirera G, Clotet B, Negredo E. Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients. Biomed Res Int 2014;2014:823058. [PMID: 25170515 DOI: 10.1155/2014/823058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
51 Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ Jr; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 2018;78:62-72. [PMID: 29419568 DOI: 10.1097/QAI.0000000000001642] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 10.7] [Reference Citation Analysis]
52 Opsomer M, Dimitrova D, Verspeelt J, Purrington A, Mehbob A, Chavers S, Pai H, Vanveggel S, Luo D, Brown K, Moecklinghoff C, Nettles RE, Boven K. Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir. Drugs R D 2018;18:199-210. [PMID: 29992490 DOI: 10.1007/s40268-018-0238-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
53 Mocumbi AO, Dobe I, Cândido S, Kim N. Cardiovascular risk and D-dimer levels in HIV-infected ART-naïve Africans. Cardiovasc Diagn Ther 2020;10:526-33. [PMID: 32695632 DOI: 10.21037/cdt.2019.12.02] [Reference Citation Analysis]
54 De Luca A, de Gaetano Donati K, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, Sighinolfi L, Giacometti A, Capobianchi MR, D'Avino A, Iacoviello L, Cauda R, D'Arminio Monforte A. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis 2013;13:414. [PMID: 24004495 DOI: 10.1186/1471-2334-13-414] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
55 Rao SG, Galaviz KI, Gay HC, Wei J, Armstrong WS, Del Rio C, Narayan KMV, Ali MK. Factors Associated With Excess Myocardial Infarction Risk in HIV-Infected Adults: A Systematic Review and Meta-analysis. J Acquir Immune Defic Syndr 2019;81:224-30. [PMID: 30865179 DOI: 10.1097/QAI.0000000000001996] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
56 Dimala CA, Blencowe H. Association between highly active antiretroviral therapy and selected cardiovascular disease risk factors in sub-Saharan Africa: a systematic review and meta-analysis protocol. BMJ Open 2017;7:e013353. [PMID: 28279997 DOI: 10.1136/bmjopen-2016-013353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
57 Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging health 2008;4:615-27. [PMID: 19915688 DOI: 10.2217/1745509X.4.6.615] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
58 Kameczura T, Bryniarski L, Surowiec S, Kocowska M, Kawecka-Jaszcz K, Czarnecka D. Myocardial infarction caused by pharmacological substances - case description and literature review. Postepy Kardiol Interwencyjnej 2013;9:250-5. [PMID: 24570727 DOI: 10.5114/pwki.2013.37504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Nance RM, Crane HM, Ritchings C, Rosenblatt L, Budoff M, Heckbert SR, Drozd DR, Mathews WC, Geng E, Hunt PW, Feinstein MJ, Moore RD, Hsue P, Eron JJ, Burkholder GA, Rodriguez B, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC. Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. AIDS Res Hum Retroviruses 2018;34:916-21. [PMID: 29984593 DOI: 10.1089/AID.2018.0053] [Reference Citation Analysis]
60 Calza DL, Manfredi R, Chiodo F. Cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Expert Opinion on Therapeutic Patents 2006;16:1497-516. [DOI: 10.1517/13543776.16.11.1497] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Annamalai L, Westmoreland SV, Domingues HG, Walsh DG, Gonzalez RG, O'Neil SP. Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleotide reverse transcriptase inhibitors. PLoS One 2010;5:e14429. [PMID: 21203448 DOI: 10.1371/journal.pone.0014429] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
62 Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, Niero F, Biasin M, Bonfanti P, Ricci ED, Trabattoni D, Clerici M. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS 2013;27:381-9. [PMID: 23079800 DOI: 10.1097/QAD.0b013e32835abcc9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
63 Baker JV, Henry WK, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 2009;4:176-82. [PMID: 19532047 DOI: 10.1097/COH.0b013e328329c62f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
64 Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier J. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE). J Acquir Immune Defic Syndr 2014;66:155-63. [PMID: 24562349 DOI: 10.1097/QAI.0000000000000131] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
65 van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19. [PMID: 15526045 DOI: 10.1371/journal.pmed.0010019] [Cited by in Crossref: 170] [Cited by in F6Publishing: 157] [Article Influence: 9.4] [Reference Citation Analysis]
66 Yehia BR, Fleishman JA, Hicks PL, Ridore M, Moore RD, Gebo KA; HIV Research Network. Inpatient health services utilization among HIV-infected adult patients in care 2002-2007. J Acquir Immune Defic Syndr 2010;53:397-404. [PMID: 19841589 DOI: 10.1097/QAI.0b013e3181bcdc16] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
67 Crane HM, Heckbert SR, Drozd DR, Budoff MJ, Delaney JA, Rodriguez C, Paramsothy P, Lober WB, Burkholder G, Willig JH, Mugavero MJ, Mathews WC, Crane PK, Moore RD, Napravnik S, Eron JJ, Hunt P, Geng E, Hsue P, Barnes GS, McReynolds J, Peter I, Grunfeld C, Saag MS, Kitahata MM; Centers for AIDS Research Network of Integrated Clinical Systems Cohort Investigators. Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. Am J Epidemiol 2014;179:996-1005. [PMID: 24618065 DOI: 10.1093/aje/kwu010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
68 Hansen L, Parker I, Roberts LM, Sutliff RL, Platt MO, Gleason RL Jr. Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice. J Biomech 2013;46:1540-7. [PMID: 23623314 DOI: 10.1016/j.jbiomech.2013.03.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
69 Batte C, Mukisa J, Rykiel N, Mukunya D, Checkley W, Knauf F, Kalyesubula R, Siddharthan T. Acceptability of patient-centered hypertension education delivered by community health workers among people living with HIV/AIDS in rural Uganda. BMC Public Health 2021;21:1343. [PMID: 34233648 DOI: 10.1186/s12889-021-11411-6] [Reference Citation Analysis]
70 Swanson B, Sha BE, Keithley JK, Fogg L, Nerad J, Novak R, Adeyemi O. Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Spectroscopy in Medically-Underserved HIV-Infected Persons. J Clin Lipidol 2009;3:379-84. [PMID: 20161509 DOI: 10.1016/j.jacl.2009.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
71 Thomas GP, Li X, Post WS, Jacobson LP, Witt MD, Brown TT, Kingsley LA, Phair JP, Palella FJ Jr. Associations between antiretroviral use and subclinical coronary atherosclerosis. AIDS 2016;30:2477-86. [PMID: 27490639 DOI: 10.1097/QAD.0000000000001220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
72 Pere D, Ignacio SL, Ramón T, Fernando L, Alberto T, Pompeyo V, Juan G, M José G, Paloma G, Antonio V, Jaime C, Esteban R, Bernardino R, M Luisa GA, Trinitario S, Ferran T, Juan Ramón L, Myriam G. Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. Open AIDS J 2008;2:26-38. [PMID: 18923695 DOI: 10.2174/1874613600802010026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
73 Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-8. [PMID: 16514301 DOI: 10.1097/01.aids.0000216371.76689.63] [Cited by in Crossref: 164] [Cited by in F6Publishing: 138] [Article Influence: 10.3] [Reference Citation Analysis]
74 Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection: . AIDS. [DOI: 10.1097/00002030-200418001-00003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
75 Cornwell A, Palli R, Singh MV, Benoodt L, Tyrell A, Abe JI, Schifitto G, Maggirwar SB, Thakar J. Molecular characterization of atherosclerosis in HIV positive persons. Sci Rep 2021;11:3232. [PMID: 33547350 DOI: 10.1038/s41598-021-82429-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005;150:933. [PMID: 16290967 DOI: 10.1016/j.ahj.2005.06.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
77 Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, Hart R, Wei SC, Loustalot F, Brooks JT, Buchacz K. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. Clin Infect Dis 2016;63:1508-16. [PMID: 27613562 DOI: 10.1093/cid/ciw615] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
78 Kebodeaux CD, Wilson AG, Smith DL, Vouri SM. A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV. HIV AIDS (Auckl) 2013;5:263-74. [PMID: 24068878 DOI: 10.2147/HIV.S36311] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Patel SM, Thames AD, Arbid N, Panos SE, Castellon S, Hinkin CH. The aggregate effects of multiple comorbid risk factors on cognition among HIV-infected individuals. J Clin Exp Neuropsychol 2013;35:421-34. [PMID: 23547924 DOI: 10.1080/13803395.2013.783000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
80 Duan M, Yao H, Hu G, Chen X, Lund AK, Buch S. HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIV-associated cardiomyopathy. PLoS One. 2013;8:e60170. [PMID: 23555914 DOI: 10.1371/journal.pone.0060170] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
81 Suchindran S, Regan S, Meigs JB, Grinspoon SK, Triant VA. Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients. Open Forum Infect Dis 2014;1:ofu076. [PMID: 25734156 DOI: 10.1093/ofid/ofu076] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
82 Buchacz K, Armon C, Palella FJ Jr, Novak RM, Fuhrer J, Tedaldi E, Ward D, Mayer C, Battalora L, Carlson K, Purinton S, Durham M, Li J; HIV Outpatient Study (HOPS) Investigators . The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research. Open Forum Infect Dis 2020;7:ofaa123. [PMID: 32455145 DOI: 10.1093/ofid/ofaa123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
83 Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabuddhe VV, Peprah E, Vorkoper S, Pastakia SD, Rausch D, Levitt NS; NIH HIV/NCD Project Disease Condition Technical Operating Group. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. AIDS 2018;32 Suppl 1:S5-S20. [PMID: 29952786 DOI: 10.1097/QAD.0000000000001888] [Cited by in Crossref: 101] [Cited by in F6Publishing: 74] [Article Influence: 25.3] [Reference Citation Analysis]
84 Moro H, Tsukada H, Tanuma A, Shirasaki A, Iino N, Nishibori T, Nishi S, Gejyo F. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS 2004;18:687-90. [PMID: 15659879 DOI: 10.1089/apc.2004.18.687] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
85 Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726-34. [PMID: 17278068 DOI: 10.1086/511679] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 8.8] [Reference Citation Analysis]
86 Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, Tien P, Bacchetti P, Scherzer R, Grunfeld C. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr. 2008;48:142-148. [PMID: 18344877 DOI: 10.1097/qai.0b013e3181685727] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
87 Metkus TS Jr, Brown TT, Post WS. Cardiovascular disease associated with the human immunodeficiency virus: an update. Curr Treat Options Cardiovasc Med 2014;16:346. [PMID: 25193559 DOI: 10.1007/s11936-014-0346-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
88 Ogunbayo GO, Ha LD, Ahmad Q, Misumida N, Okwechime R, Elbadawi A, Abdel-Latif A, Elayi CS, Smyth S, Boccara F, Messerli AW. Treatment Bias in Management of HIV Patients Admitted for Acute Myocardial Infarction: Does It Still Exist? J Gen Intern Med 2020;35:57-62. [PMID: 31713036 DOI: 10.1007/s11606-019-05416-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
89 Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005;19:641-52. [PMID: 15821390 DOI: 10.1097/01.aids.0000166087.08822.bc] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
90 Monteiro P, Miranda-Filho DB, Bandeira F, Lacerda HR, Chaves H, Albuquerque MF, Montarroyos UR, Ximenes RA. Is arterial stiffness in HIV-infected individuals associated with HIV-related factors? Braz J Med Biol Res 2012;45:818-26. [PMID: 22782555 DOI: 10.1590/s0100-879x2012007500116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
91 Lange DC, Glidden D, Secemsky EA, Ordovas K, Deeks SG, Martin JN, Bolger AF, Hsue PY. Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals. PLoS One 2015;10:e0130592. [PMID: 26132465 DOI: 10.1371/journal.pone.0130592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
92 Murphy R, Costagliola D. Increased cardiovascular risk in HIV infection: drugs, virus and immunity. AIDS 2008;22:1625-7. [PMID: 18670222 DOI: 10.1097/QAD.0b013e328306a6db] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
93 Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med 2008;148:178-85. [PMID: 18252681 DOI: 10.7326/0003-4819-148-3-200802050-00004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
94 Puddu P, Puddu GM, Cravero E, De Pascalis S, Muscari A. The emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis. J Biomed Sci. 2009;16:112. [PMID: 20003216 DOI: 10.1186/1423-0127-16-112] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
95 Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94. [PMID: 15821394 DOI: 10.1097/01.aids.0000166091.39317.99] [Cited by in Crossref: 174] [Cited by in F6Publishing: 157] [Article Influence: 10.2] [Reference Citation Analysis]
96 Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon. PLoS One 2016;11:e0148100. [PMID: 26862763 DOI: 10.1371/journal.pone.0148100] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
97 Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011;6:266-71. [PMID: 21546831 DOI: 10.1097/COH.0b013e328347876c] [Cited by in Crossref: 68] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
98 Siedner MJ. START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection. Open Forum Infect Dis 2016;3:ofw032. [PMID: 26989755 DOI: 10.1093/ofid/ofw032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
99 Whiteside YO, Selik R, An Q, Huang T, Karch D, Hernandez AL, Hall HI. Comparison of Rates of Death Having any Death-Certificate Mention of Heart, Kidney, or Liver Disease Among Persons Diagnosed with HIV Infection with those in the General US Population, 2009-2011. Open AIDS J 2015;9:14-22. [PMID: 25767634 DOI: 10.2174/1874613601509010014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
100 Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M; Working Group 2. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35. [PMID: 18566319 DOI: 10.1161/CIRCULATIONAHA.107.189624] [Cited by in Crossref: 233] [Cited by in F6Publishing: 133] [Article Influence: 16.6] [Reference Citation Analysis]
101 Ekrikpo UE, Akpan EE, Ekott JU, Bello AK, Okpechi IG, Kengne AP. Prevalence and correlates of traditional risk factors for cardiovascular disease in a Nigerian ART-naive HIV population: a cross-sectional study. BMJ Open 2018;8:e019664. [PMID: 30030310 DOI: 10.1136/bmjopen-2017-019664] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
102 Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008;46:1101-10. [PMID: 18461712 DOI: 10.1086/528862] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
103 Mondy KE, de las Fuentes L, Waggoner A, Onen NF, Bopp CS, Lassa-Claxton S, Powderly WG, Dávila-Román V, Yarasheski KE. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS 2008;22:849-56. [PMID: 18427203 DOI: 10.1097/QAD.0b013e3282f70694] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
104 . 8.0 Antiretroviral therapy in specific populations: BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2014;15:58-81. [DOI: 10.1111/hiv.12119_9] [Reference Citation Analysis]
105 Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86. [PMID: 14600519 DOI: 10.1097/00002030-200311210-00010] [Cited by in Crossref: 393] [Cited by in F6Publishing: 356] [Article Influence: 20.7] [Reference Citation Analysis]
106 Lumsden RH, Bloomfield GS. The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds. Biomed Res Int 2016;2016:8196560. [PMID: 26885518 DOI: 10.1155/2016/8196560] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
107 Miller PE, Haberlen SA, Metkus T, Rezaeian P, Palella F, Kingsley LA, Witt MD, George RT, Jacobson LP, Brown TT, Budoff M, Post WS. HIV and coronary arterial remodeling from the Multicenter AIDS Cohort Study (MACS). Atherosclerosis 2015;241:716-22. [PMID: 26132282 DOI: 10.1016/j.atherosclerosis.2015.06.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
108 Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases 2017; 5(2): 40-45 [PMID: 28255546 DOI: 10.12998/wjcc.v5.i2.40] [Reference Citation Analysis]
109 Gallant JE. Should antiretroviral therapy be started earlier? Curr HIV/AIDS Rep 2007;4:53-9. [PMID: 17547825 DOI: 10.1007/s11904-007-0008-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
110 Knudsen AD, Graff C, Nielsen JB, Thomsen MT, Høgh J, Benfield T, Gerstoft J, Køber L, Kofoed KF, Nielsen SD. De novo electrocardiographic abnormalities in persons living with HIV. Sci Rep 2021;11:20750. [PMID: 34675281 DOI: 10.1038/s41598-021-00290-x] [Reference Citation Analysis]
111 Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005;21:757-67. [PMID: 16218799 DOI: 10.1089/aid.2005.21.757] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 5.1] [Reference Citation Analysis]
112 Schambelan M, Wilson PW, Yarasheski KE, Cade WT, Dávila-Román VG, D'Agostino RB Sr, Helmy TA, Law M, Mondy KE, Nachman S, Peterson LR, Worm SW; Working Group 5. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008;118:e48-53. [PMID: 18566316 DOI: 10.1161/CIRCULATIONAHA.107.189627] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
113 Nkambule BB, Mkandla Z, Mutize T, Dludla PV. Platelet function and cardiovascular risk in adult HIV-infected patients on HAART: a protocol for a systematic review and meta-analysis. BMJ Open 2017;7:e019468. [PMID: 29259066 DOI: 10.1136/bmjopen-2017-019468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
114 Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010;24:789-802. [PMID: 20224307 DOI: 10.1097/QAD.0b013e328337afdf] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
115 Jiang B, Hebert VY, Khandelwal AR, Stokes KY, Dugas TR. HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. Toxicol Lett 2009;187:164-71. [PMID: 19429260 DOI: 10.1016/j.toxlet.2009.02.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
116 Patel P, Sabin K, Godfrey-Faussett P. Approaches to Improve the Surveillance, Monitoring, and Management of Noncommunicable Diseases in HIV-Infected Persons: Viewpoint. JMIR Public Health Surveill 2018;4:e10989. [PMID: 30573446 DOI: 10.2196/10989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
117 Nirmala N, Avendano EE, Morin RA. Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis. Infect Dis (Lond) 2021;:1-11. [PMID: 34590982 DOI: 10.1080/23744235.2021.1982140] [Reference Citation Analysis]
118 Sekhar RV, Jahoor F, Pownall HJ, Ballantyne CM, Balasubramanyam A. Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Curr Atheroscler Rep 2004;6:173-9. [PMID: 15068741 DOI: 10.1007/s11883-004-0029-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
119 Gebo KA, Justice A. HIV infection in the elderly. Curr Infect Dis Rep 2009;11:246-54. [PMID: 19366568 DOI: 10.1007/s11908-009-0036-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
120 Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006;20:1941-50. [PMID: 16988515 DOI: 10.1097/01.aids.0000247115.81832.a1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
121 Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, Harrill D, Tungsiripat M, Adell J, McComsey GA. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009;49:1119-27. [PMID: 19712036 DOI: 10.1086/605578] [Cited by in Crossref: 165] [Cited by in F6Publishing: 169] [Article Influence: 12.7] [Reference Citation Analysis]
122 Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol 2019;16:745-59. [PMID: 31182833 DOI: 10.1038/s41569-019-0219-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
123 Spieker LE, Karadag B, Binggeli C, Corti R. Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection. Heart Vessels 2005;20:171-4. [PMID: 16025368 DOI: 10.1007/s00380-004-0790-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
124 Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH; SABAR Study Team. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 2010;24:885-90. [PMID: 19952712 DOI: 10.1097/QAD.0b013e3283352ed5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
125 Barbaro G. Heart and HAART: Two sides of the coin for HIV-associated cardiology issues. World J Cardiol 2010; 2(3): 53-57 [PMID: 21160756 DOI: 10.4330/wjc.v2.i3.53] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
126 Singh MV, Kotla S, Le NT, Ae Ko K, Heo KS, Wang Y, Fujii Y, Thi Vu H, McBeath E, Thomas TN, Jin Gi Y, Tao Y, Medina JL, Taunton J, Carson N, Dogra V, Doyley MM, Tyrell A, Lu W, Qiu X, Stirpe NE, Gates KJ, Hurley C, Fujiwara K, Maggirwar SB, Schifitto G, Abe JI. Senescent Phenotype Induced by p90RSK-NRF2 Signaling Sensitizes Monocytes and Macrophages to Oxidative Stress in HIV-Positive Individuals. Circulation 2019;139:1199-216. [PMID: 30586719 DOI: 10.1161/CIRCULATIONAHA.118.036232] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
127 Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H; GS-US-380–4030 Investigators. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis 2021;73:e485-93. [PMID: 32668455 DOI: 10.1093/cid/ciaa988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
128 Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurol 2012;11:878-90. [PMID: 22995692 DOI: 10.1016/S1474-4422(12)70205-3] [Cited by in Crossref: 150] [Cited by in F6Publishing: 76] [Article Influence: 15.0] [Reference Citation Analysis]
129 Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, Holmberg SD, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008;22:1345-54. [PMID: 18580614 DOI: 10.1097/QAD.0b013e328304b38b] [Cited by in Crossref: 103] [Cited by in F6Publishing: 68] [Article Influence: 7.4] [Reference Citation Analysis]
130 D’Ascenzo F, Cerrato E, Biondi-Zoccai G, Moretti C, Omedè P, Sciuto F, Bollati M, Modena MG, Gaita F, Sheiban I. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J. 2012;33:875-880. [PMID: 22187508 DOI: 10.1093/eurheartj/ehr456] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 7.0] [Reference Citation Analysis]
131 Jong E, Louw S, Meijers JC, de Kruif MD, ten Cate H, Büller HR, Mulder JW, van Gorp EC. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009;23:1001-7. [PMID: 19929230 DOI: 10.1089/apc.2009.0173] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
132 Nadler J. New anti-HIV protease inhibitors provide more treatment options. AIDS Patient Care STDS 2003;17:551-64. [PMID: 14746663 DOI: 10.1089/108729103322555944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
133 Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, Mays ME, Sosman JM. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004;147:E18. [PMID: 15077088 DOI: 10.1016/j.ahj.2003.10.018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.1] [Reference Citation Analysis]
134 Cotter BR. Endothelial dysfunction in HIV infection. Curr HIV/AIDS Rep 2006;3:126-31. [PMID: 16970839 DOI: 10.1007/BF02696656] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
135 Whelton SP, Deal JA, Zikusoka M, Jacobson LP, Sarkar S, Palella FJ Jr, Kingsley L, Budoff M, Witt MD, Brown TT, Post WS. Associations between lipids and subclinical coronary atherosclerosis. AIDS 2019;33:1053-61. [PMID: 30946159 DOI: 10.1097/QAD.0000000000002151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
136 Yuan N, Scherzer R, Tanriverdi K, Martin J, Rahalkar S, Hsue P. MicroRNA biomarkers associated with type 1 myocardial infarction in HIV-positive individuals. AIDS 2019;33:2351-61. [PMID: 31764100 DOI: 10.1097/QAD.0000000000002368] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
137 Rasmussen LD, Omland LH, Pedersen C, Gerstoft J, Kronborg G, Jensen J, Obel N. Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study. BMC Infect Dis 2010;10:169. [PMID: 20546604 DOI: 10.1186/1471-2334-10-169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
138 Ho JE, Scherzer R, Hecht FM, Maka K, Selby V, Martin JN, Ganz P, Deeks SG, Hsue PY. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012;26:1115-20. [PMID: 22382147 DOI: 10.1097/QAD.0b013e328352ce54] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
139 Eyawo O, Brockman G, Goldsmith CH, Hull MW, Lear SA, Bennett M, Guillemi S, Franco-Villalobos C, Adam A, Mills EJ, Montaner JSG, Hogg RS. Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis. BMJ Open 2019;9:e025874. [PMID: 31551371 DOI: 10.1136/bmjopen-2018-025874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
140 Osoti A, Temu TM, Kirui N, Ngetich EK, Kamano JH, Page S, Farquhar C, Bloomfield GS. Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. AIDS Patient Care STDS 2018;32:215-22. [PMID: 29851503 DOI: 10.1089/apc.2018.0052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
141 Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT; HIV Outpatient Study Investigators. Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2015;69:306-11. [PMID: 26181706 DOI: 10.1097/QAI.0000000000000581] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
142 Kozić Dokmanović S, Kolovrat K, Laškaj R, Jukić V, Vrkić N, Begovac J. Effect of Extra Virgin Olive Oil on Biomarkers of Inflammation in HIV-Infected Patients: A Randomized, Crossover, Controlled Clinical Trial. Med Sci Monit 2015;21:2406-13. [PMID: 26280823 DOI: 10.12659/MSM.893881] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
143 Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J 2011;5:49-63. [PMID: 21643501 DOI: 10.2174/1874192401105010049] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 7.6] [Reference Citation Analysis]
144 Stein JH, Brown TT, Ribaudo HJ, Chen Y, Yan M, Lauer-Brodell E, McComsey GA, Dubé MP, Murphy RL, Hodis HN, Currier JS. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2013;27:929-37. [PMID: 23196938 DOI: 10.1097/QAD.0b013e32835ce27e] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
145 Kingsley LA, Cuervo-Rojas J, Muñoz A, Palella FJ, Post W, Witt MD, Budoff M, Kuller L. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS 2008;22:1589-99. [PMID: 18670218 DOI: 10.1097/QAD.0b013e328306a6c5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
146 Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, Horsburgh CR Jr. Endothelial function in HIV-infected persons. Clin Infect Dis 2006;42:1325-32. [PMID: 16586393 DOI: 10.1086/503261] [Cited by in Crossref: 129] [Cited by in F6Publishing: 134] [Article Influence: 8.1] [Reference Citation Analysis]
147 Bailin SS, Jenkins CA, Petucci C, Culver JA, Shepherd BE, Fessel JP, Hulgan T, Koethe JR. Lower Concentrations of Circulating Medium and Long-Chain Acylcarnitines Characterize Insulin Resistance in Persons with HIV. AIDS Res Hum Retroviruses 2018;34:536-43. [PMID: 29607651 DOI: 10.1089/AID.2017.0314] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]